Reports Q3 revenue $378k, consensus $1.58M. “This quarter marks a pivotal inflection point for Absci (ABSI) as we sharpen our focus on ABS-201, advancing this program in two high-value indications with strong biological rationale and significant unmet need,” said Sean McClain, Founder and CEO. “By reallocating our resources toward the PRLR mechanism in androgenetic alopecia and endometriosis, we’re positioned to create meaningful impact for patients while driving the greatest return for shareholders. Our strategy reflects disciplined execution and confidence in the power of generative AI protein design to deliver breakthrough therapeutics.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- AbSci Corp options imply 13.2% move in share price post-earnings
- ABSI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Absci Finalizes Milestone Distribution Agreement with SBGH
- Absci to host KOL seminar on ABS-201 androgenetic alopecia program
- Absci participates in a conference call with JPMorgan